1. A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults.
- Author
-
Peterson RD, Guarneiri LL, Adams CG, Wilcox ML, Clark AJ, Rudemiller NP, Maki KC, and Malinczak CA
- Subjects
- Humans, Double-Blind Method, Adult, Male, Female, Young Adult, Middle Aged, Recombinant Proteins immunology, Animals, Antibodies blood, Dose-Response Relationship, Drug, Cattle, Healthy Volunteers, Lactoferrin administration & dosage, Lactoferrin immunology
- Abstract
Recombinant human lactoferrin (rhLF) is of commercial interest for immune support as a food ingredient. The objective was to evaluate the immunogenicity/alloimmunization potential of Helaina rhLF (effera™) from K. phaffii over a 28-day period compared to bovine LF (bLF). Study 1 was a randomized, double-blind, parallel arm, controlled trial where 66 healthy adults were randomly allocated to 1 of 3 groups: high-dose rhLF (3.4 g/d), low-dose rhLF (0.34 g/d), or bLF (3.4 g/d). Participants completed a 28-day supplementation period with follow-up visits on Days 28, 56, and 84. Study 2 was a 12-week observational study with no intervention that enrolled 24 healthy adults. In both studies, serum was obtained for analysis of anti-LF antibody levels as the primary endpoint. In Study 1, change from baseline to Day 56 in serum anti-bLF antibodies in the bLF group (least squares geometric mean and 95% confidence interval for the post/pre ratio: 3.01; 2.08, 4.35) was greater than the changes in serum anti-hLF antibodies in the low-dose rhLF (1.07; 0.77, 1.49; P < 0.001) and high-dose rhLF (1.02; 0.62, 1.70; P < 0.001) groups. The rhLF groups had similar changes to the observational study, indicating no change in anti-hLF antibodies and no evidence of alloimmunization following ingestion. Changes in safety outcomes were similar between groups and within normal ranges. These results show that under the conditions of the protocol, no increased anti-hLF antibodies or adverse events were identified following ingestion of effera™ as a food ingredient at an intake level up to 3.4 g/d in healthy adults (clinicaltrials.gov: NCT06012669)., Competing Interests: Declaration of Conflicting InterestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Nathan Rudemiller received consulting or advisory fees from Helaina Inc. Carrie-Anne Malinczak, Ross Peterson, and Anthony Clark are employees of Helaina Inc. and receives equity or stocks in the company. As employees of Midwest Biomedical Research, Kevin Maki, Liana Guarneiri, Caryn Adams, and Meredith Wilcox receive grants and/or consulting fees from 89bio Inc., Beren Therapeutics P.B.C., Cargill Inc., General Mills Inc., Greenyn Biotechnology Co. Ltd., Hass Avocado Board, Helaina Inc., Indiana University Foundation, Matinas BioPharma Holdings Inc., National Cattleman’s Beef Association, National Dair Council, Naturmega, PepsiCo Inc., Pharmavite LLC, NewAmsterdam Pharma, Bragg Live Products, Campbell Soup Company, Eli Lilly and Company, Medifast Inc., NeuroEnergy Ventures, and Seed Inc.
- Published
- 2025
- Full Text
- View/download PDF